in this issue
Endocrine resistance in breast cancer: what really matters?
Breast cancer prognostication and prediction in the postgenomic era
New drug development in digestive neuroendocrine tumors
Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrine-responsive tumours? Lessons from a series in a single institution
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma
Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type
An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-α2b in patients with multiple myeloma maintained on a steady dose of interferon-α2b
The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study
Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors
Prognosis for long-term survivors of cancer
Association between glycosylated hemoglobin and cancer risk: a New Zealand linkage study
Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells
Lymphoma and human immunodeficiency virus (HIV) infection: another favourable setting?
Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004
The other side of p53